Potential conflict of interest: AA: nothing to disclose. NR: Research: Gilead, Vertex, Genentech, AbbVie. Advisory: Gilead, Janssen, AbbVie, Vertex, Idenix. DJ: Research grants: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, Janssen, Vertex. Consultations: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, Idenix, Janssen.
Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus
Version of Record online: 1 MAR 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 5, pages 1688–1691, May 2014
How to Cite
Aronsohn, A., Reau, N. and Jensen, D. (2014), Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus. Hepatology, 59: 1688–1691. doi: 10.1002/hep.26903
- Issue online: 23 APR 2014
- Version of Record online: 1 MAR 2014
- Accepted manuscript online: 21 OCT 2013 12:31PM EST
- Manuscript Accepted: 15 OCT 2013
- Manuscript Received: 16 SEP 2013
- 12FDA. Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices. Department of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Policy. January 2009. Available at: www.fda.gov/regulatoryinformation/guidances/ucm125126.htm. Accessed on September 2, 2013.
- 14COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. Presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March 3-6, 2013, , , , , , et al.